ghk-cu subcutaneo Peptide GHK-Cu has gained major attention

in this role, was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum Mnchen as, for example, WO/2016/188932 A2 or WO/2017/194499 A1

It's unclear how they'll weigh the findings of the career scientists at the FDA who state there's insufficient evidence to support changing the designation for any of the seven peptides under consideration

10.1371/journal.pone.0107421 155

Safety is favorable but irrelevant to efficacy

If the claims examiner or medical consultant finds your impairments don't (or shouldn't) significantly limit the work you could do, DDS will consider your impairment "not severe" (or non-severe, mild, or slight)